MANKIND PHARMA LIMITED
Company's authorized capital stands at Rs 4100.0 lakhs and has 97.7045% paid-up capital which is Rs 4005.88 lakhs. Mankind Pharma Limited last annual general meet (AGM) happened on 23 Sep, 2017. The company last updated its financials on 31 Mar, 2017 as per Ministry of Corporate Affairs (MCA).
Mankind Pharma Limited is majorly in Business Services business from last 33 years and currently, company operations are active. Current board members & directors are SURENDRA LUNIA, RAMESH JUNEJA, RAJEEV JUNEJA, RAJEEV JUNEJA, PRABHA ARORA, PREM KUMAR ARORA, SHEETAL ARORA, ARJUN JUNEJA, PRADEEP CHUGH, ASHUTOSH KUMAR DHAWAN, SANDIP SHARMA, ANUJ GIROTRA, LEONARD LEE KIM and SATISH KUMAR SHARMA .
Company is registered in Delhi (Delhi) Registrar Office. Mankind Pharma Limited registered address is 208, Okhla Industrial Estate, Phase-III, New Delhi South Delhi DL 110020 IN.
Mankind Pharma Limited Details
| CIN | U74899DL1991PLC044843 |
| Date of Incorporation | 03 Jul, 1991 |
| Status | Active |
| Company Category | Company limited by Shares |
| Company Sub-category | Non-govt company |
| Company Class | Public |
| Business Activity | Business Services |
| Authorized Capital | 4100.0 lakhs |
| Paid-up Capital | 4005.88 lakhs |
| Paid-up Capital % | 97.7045 |
| Registrar Office City | Delhi |
| Registered State | Delhi |
| Registration Number | 44843 |
| Registration Date | 03 Jul, 1991 |
| Listing Status | Unlisted |
| AGM last held on | 23 Sep, 2017 |
| Balance Sheet last updated on | 31 Mar, 2017 |
Mankind Pharma Limited News
Motilal Oswal initiates coverage on Mankind Pharma with target price of Rs 2,650
Motilal Oswal initiated coverage on Mankind Pharma with a 'buy' call and target price of Rs 2,650. The company's disruptive strategy in establishing its DF business has made it an industry leader in prescriptions.
Hot Stocks: Brokerage view on Tata Consumer, Varun Beverages and Mankind Pharma
Top brokerage firms like Motilal Oswal, Jefferies, and Morgan Stanley have issued buy ratings and targets for Mankind Pharma, Nykaa, Tata Consumer, and Varun Beverages.
Pankaj Pandey on 4 sectors that may outperform in near term
But our overall sense is that one needs to sort of watch out for Budget plus the element of optimism. Although they have some head room in terms of higher RBI dividend plus, obviously there can be structural savings on the subsidy side especially related to fertilisers, so it remains to be seen how they sort of utilise.
Buy Mankind Pharma, target price Rs 2650: Motilal Oswal
Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 89132.93 Crore) operating in Pharmaceuticals sector.
Block deals worth over Rs 7,640 crore this week. Chandrababu Naidu’s Heritage Foods, Adani Ports see top action
The week was an eventful one. Besides the general election results, D-Street saw some prominent block deals which included over three dozen companies from large, mid and smallcap segments. Shares worth Rs 7,640 crore were traded on screen, which included both buying and selling.
Mankind Pharma scouts for M&A deals to boost local branded biz
Mankind Pharma, the fourth-largest pharmaceutical company in India, led by Rajeev Juneja, is seeking mergers, acquisitions, and in-licensing deals to enhance its branded formulation business.
Stocks with tailwinds called advantage India: 5 largecap stocks from 3 different sectors with an upside potential of upto 36 %
In terms of valuations and sentiment we are not far from the place where we were in the last quarter of 2023 or early part of this year. When it was not possible to find stocks which can be called as “fairly valued” forget “undervalued”, and the sentiment was very bullish. The only difference between then and now is that we have election results which are coming up. Surely a confirmation on 4th June that continuity in the policy making is a big factor. But there is another thing which long term investors need to look at before investing. Whether the company or the sector has an advantage due to India as a country. A well known example, which has been present for decades is that of the IT industry. India as a country is a factory of software engineers, and that is our strength. So when investing for the long term, look at sectors where we have some strong tailwinds due to our human capital.
Local pharma companies queue up for JB Chemicals & Pharmaceuticals
Mankind Pharma, Dr Reddy’s Laboratories, and Torrent Pharma are interested in acquiring JB Chemicals & Pharmaceuticals from KKR. Private equity funds are discouraged by high valuation, with first round of bids expected soon.
Local pharma companies queue up for JB Chemicals & Pharmaceuticals
Mankind Pharma, Dr Reddy's Laboratories, and Torrent Pharma are interested in acquiring JB Chemicals & Pharmaceuticals from KKR. KKR's investment arm, TAU Investment, owns 53.78% in JB Chemicals, worth Rs 14,020 crore. The company's revenue doubled to Rs 3,484 crore in FY24 under KKR's ownership. JB Chemicals has made four acquisitions in the last four years, investing $200 million. However, global private equity funds are not pushing for JB Chemicals due to high valuations.
Bullish on NALCO, IOC & SAIL; Honeywell to touch Rs 1 lakh in future: Sanjiv Bhasin
Sanjiv Bhasin of IIFL Securities predicts Honeywell Automation's share price is going to reach Rs 1 lakh, while he had bought it years ago for Rs 89. Strong market performances by Hindustan Aeronautics and Mahindra indicate stability amidst FII selling worries. Opportunities in PSUs like NALCO, IOC, and SAIL emerge in the current market scenario.
* Ministry of Corporate Affairs, 2019, Company/LLP Data, (Government of India administrative body to govern and regulate corporate affairs through the Companies Act 1956 & 2013 including other allied Acts, Bills and Rules) http://www.mca.gov.in/, Updated as on 04 Dec, 2018.
Please Note: Data on this page may not be updated vis-à-vis company’s current credentials.
